The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types ...

There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

In this photo illustration, the Merck & Co., Inc. logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor ...

Merck (MRK) ended the recent trading session at $117.17, demonstrating a -0.05% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.19%.

Keytruda shows promise as a first line option in cervical cancer cutting patients' mortality risk by a third in a Phase 3 ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $117.96 which represents a slight increase of $2.10 or 1.81% from the prior close of $115.86. The stock opened at $115.8 and touched a ...

Moderna (MRNA) plans to launch a skin cancer vaccine developed with Merck (MRK) in 2025, but faces stock pressure after ...

As of 20 September at 3:59 pm GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

Jefferies analyst Akash Tewari maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

As of 19 September at 9:54 am GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.